ACVR1 and fibrodysplasia ossificans progressiva: The discovery of mutations in the ACVR1/ALK2 as the etiology of FOP provides emerging targeted therapies and certain such therapeutic strategies are in development which hold great promise for managing FOP [38,, 39].